NCT05880758 Impact of Yo-Yo Sleep on Cardiometabolic Health
| NCT ID | NCT05880758 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Cardiometabolic Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2023-09-22 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2023-09-22 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to test the impact of repeated intermittent short sleep, with short sleep maintained 5 days per week followed by 2 days of prolonged sleep, compared to daily adequate sleep, on energy balance and cardiometabolic risk. A secondary goal of this research is to determine if maintaining a constant midpoint of sleep while undergoing intermittent short sleep, leads to better outcomes than intermittent short sleep with a 2-hour delay in sleep midpoint. The aims of this research will be tested in the context of a 3-group, parallel-arm, outpatient intervention of 4 weeks in duration, in young-to-middle-aged adults (aged 18-49 years).
Eligibility Criteria
Inclusion Criteria: * Aged 18 to 49 years * BMI 20-29.9 kg/m2 * Habitually sleeping 7-9 hours/night without sleep aids or naps Exclusion Criteria: * Sleep disorders * Psychiatric disorders (including eating disorders) and seasonal affective disorder * Pregnancy (current/prior year) * Breastfeeding * Smokers (Any cigarette smoking or ex-smokers \<3years) * Diabetes * Elevated blood pressure, taking beta-blockers * Individuals taking anti-coagulants or anti-platelets * Recent weight change or participation in a weight loss program or have ever had bariatric surgery or other weight loss or gastrointestinal procedure. * Travel across time zones; shift work (non-traditional hours)
Contact & Investigator
Marie-Pierre St-Onge, PhD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT05880758 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 49 Years, studying Cardiometabolic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05880758 currently recruiting?
Yes, NCT05880758 is actively recruiting participants. Contact the research team at ms2554@cumc.columbia.edu for enrollment information.
Where is the NCT05880758 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05880758 clinical trial?
NCT05880758 is sponsored by Columbia University. The principal investigator is Marie-Pierre St-Onge, PhD at Columbia University. The trial plans to enroll 72 participants.